Clinical Trial

Precision Medicine for Stem Cell Transplantation

Study acronym: PM-SCT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
A study of patients undergoing haematopoietic stem cell transplantation, a procedure in which patients are infused with stem cells from a donor, resulting in a new immune system that eliminates cancer or replaces diseased bone marrow. This study aims to develop new blood tests that predict the onset of acute graft-versus-host disease (aGvHD) and leukaemia relapse, two life-threatening complications that frequently limit the success of treatment. Predictive tests would allow doctors to individualise prophylaxis and intervene early to abort complications before they develop. The study will also create a large collection of clinically annotated blood samples from 300 transplant recipients to support future research and provide a resource to the transplant research community.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-10-04; most recent amendment 2025-03-31.
Status change: Not Yet Recruiting → Recruiting 2023-06-26
Trial Details
NCT Number NCT05567289
Lead Sponsor University of Manchester
Collaborators: The Christie NHS Foundation Trust
Conditions Haematopoietic Stem Cell Transplantation
Enrollment 300 participants
Start Date 2023-06-06
Primary Completion 2025-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2025-04-03